The Joint Corp. (JYNT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JYNT SEC filings page.
The Joint Corp. (JYNT) reported $58.5M in revenue over the twelve months to Jun 30, 2026, down 17.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
JYNT's dominant mechanic is a shrinking revenue base colliding with a relatively fixed cost structure while leverage rises against thinner equity.
FY2025's positive net income of$2.9M coexisted with an operating loss of-$913K , creating an earnings-quality gap between reported profit and the core business. Operating cash flow was only$1.8M against free cash flow of$335K , so reported profit did not translate into much cash after reinvestment.
Revenue fell from
Debt-to-equity rose from 1.9x in FY2021 to 3.0x in FY2025 as the equity base thinned, making liabilities a larger part of the financing structure. Short-term coverage improved from 0.8x in FY2022 to 1.6x in FY2025, but that did not reverse the longer-term shift toward a more leveraged balance sheet.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of The Joint Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
The Joint Corp. has an operating margin of -1.7%, meaning the company loses $2 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -3.6% the prior year.
The Joint Corp.'s revenue grew 5.2% year-over-year to $54.9M, a solid pace of expansion. This earns a growth score of 2/100.
The Joint Corp. has elevated debt relative to equity (D/E of 3.05), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 21/100, reflecting increased financial risk.
The Joint Corp.'s current ratio of 1.59 indicates adequate short-term liquidity, earning a score of 45/100. The company can meet its near-term obligations, though with limited headroom.
While The Joint Corp. generated $1.8M in operating cash flow, capex of $1.5M consumed most of it, leaving $335K in free cash flow. This results in a low score of 53/100, reflecting heavy capital investment rather than weak cash generation.
The Joint Corp. generates a 19.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 19/100. This is up from -28.1% the prior year.
The Joint Corp. scores 2.11, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($111.0M) relative to total liabilities ($45.9M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
The Joint Corp. passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, The Joint Corp. generates $0.63 in operating cash flow ($1.8M OCF vs $2.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
The Joint Corp. generated $15.2M in revenue in Q2 2026. This represents an increase of 14.4% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.
The Joint Corp.'s EBITDA was $54K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 107.4% from the same quarter a year earlier. Against the prior quarter it is down 95.8%.
The Joint Corp. reported $653K in net income in Q2 2026. This represents an increase of 599.4% from the same quarter a year earlier. Against the prior quarter it is down 49.7%.
The Joint Corp. earned $0.05 per diluted share (EPS) in Q2 2026. This represents an increase of 400.0% from the same quarter a year earlier. Against the prior quarter it is down 44.4%.
Cash & Balance Sheet
The Joint Corp. generated $1.9M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 432.4% from the same quarter a year earlier. Against the prior quarter it is up 213.2%.
The Joint Corp. held $22.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
The Joint Corp.'s gross margin was 83.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.
The Joint Corp.'s operating margin was -2.4% in Q2 2026, reflecting core business profitability. This is up 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.
The Joint Corp.'s net profit margin was 4.3% in Q2 2026, showing the share of revenue converted to profit. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.5 percentage points.
The Joint Corp.'s ROE was 4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Capital Allocation
The Joint Corp. spent $677K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 40.9%.
The Joint Corp. invested $256K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 49.3% from the same quarter a year earlier. Against the prior quarter it is up 9.2%.
Not reported for Q2 2026.
JYNT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M+14.4% | $14.8M+13.3% | $15.2M+3.1% | $13.4M-55.7% | $13.3M-56.1% | $13.1M-56.0% | $14.7M+15.8% | $30.2M+2.5% |
| Cost of Revenue | $2.5M-10.7% | $2.7M-8.4% | $2.8M-11.5% | $2.7M-5.5% | $2.8M-1.4% | $3.0M+9.9% | $3.2M+12.1% | $2.8M+8.6% |
| Gross Profit | $12.7M+21.0% | $12.1M+19.7% | $12.3M+7.1% | $10.7M-60.9% | $10.5M-61.8% | $10.1M-62.6% | $11.5M+16.8% | $27.4M+1.9% |
| SG&A Expenses | $12.9M+10.6% | $11.2M+3.9% | $11.6M+8.9% | $10.6M+2.2% | $11.6M+0.5% | $10.8M+8.8% | $10.7M+19.8% | $10.3M+14.7% |
| Operating Income | -$369K+67.6% | $874K+228.8% | $742K-8.3% | $161K+132.7% | -$1.1M+36.0% | -$679K-59.1% | $810K-18.6% | -$493K-12811.2% |
| EBITDA | $54K+107.4% | $1.3M+540.4% | $1.2M+1.1% | $608K-18.6% | -$736K-188.0% | -$290K-129.7% | $1.2M-12.2% | $746K-68.2% |
| Income Tax | $9K-20.0% | $11K-17.1% | $4K+118.0% | $10K+91.9% | $11K+2.0% | $13K+56.2% | -$20K-100.2% | $5K+133.8% |
| Net Income | $653K+599.4% | $1.3M+34.2% | $991K+5510.5% | $855K+127.0% | $93K+102.6% | $968K+2.2% | $18K+100.2% | -$3.2M-341.9% |
| EPS (Basic) | $0.05+400.0% | $0.09+50.0% | $0.07 | $0.06+128.6% | $0.01+104.2% | $0.060.0% | $0.00+100.0% | -$0.21-320.0% |
| EPS (Diluted) | $0.05+400.0% | $0.09+50.0% | $0.07 | $0.06+128.6% | $0.01 | $0.060.0% | $0.00+100.0% | -$0.21-320.0% |
| Diluted Shares (Avg) | 14M-7.5% | 14M-7.1% | N/A | 15M+1.4% | 15M | 15M+1.7% | N/A | 15M+1.2% |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
JYNT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $51.6M-29.5% | $57.9M-27.7% | $61.0M-26.7% | $69.4M-12.8% | $73.2M-11.2% | $80.1M-6.5% | $83.2M-4.6% | $79.6M-19.2% |
| Current Assets | $43.8M-31.3% | $49.6M-29.9% | $52.1M-30.2% | $60.5M+9.7% | $63.8M+46.9% | $70.7M+58.5% | $74.6M+68.2% | $55.2M+94.1% |
| Cash & Equivalents | $22.2M-25.7% | $20.7M-5.6% | $23.6M-5.8% | $29.7M+43.2% | $29.8M+70.8% | $21.9M+16.9% | $25.1M+38.0% | $20.7M+29.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $2.4M-13.7% | $2.3M-21.1% | $2.8M+10.2% | $2.9M-32.5% | $2.8M-22.0% | $3.0M-9.1% | $2.6M+0.2% | $4.3M+17.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.2M-49.8% |
| Total Liabilities | $35.8M-28.4% | $42.4M-25.9% | $45.9M-26.6% | $46.7M-21.1% | $49.9M-15.7% | $57.3M-3.7% | $62.5M+0.1% | $59.1M-6.6% |
| Current Liabilities | $24.0M-32.5% | $30.2M-29.4% | $32.8M-33.1% | $33.0M-13.7% | $35.5M+4.4% | $42.7M+28.1% | $49.0M+46.1% | $38.3M+38.4% |
| Non-Current Liabilities | $11.8M-18.3% | $12.3M-15.8% | $13.1M-2.7% | $13.6M-34.7% | $14.4M-42.8% | $14.5M-44.3% | $13.4M-53.5% | $20.8M-41.5% |
| Total Equity | $15.9M-31.8% | $15.5M-32.2% | $15.1M-27.1% | $22.7M+11.0% | $23.2M+0.2% | $22.8M-12.9% | $20.7M-16.5% | $20.5M-42.0% |
| Retained Earnings | -$22.8M+14.3% | -$23.5M+12.1% | -$24.8M+10.5% | -$25.8M+7.0% | -$26.6M-8.5% | -$26.7M-27.6% | -$27.7M-26.5% | -$27.7M-155.2% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
JYNT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.2M+152.4% | -$1.5M+60.1% | $2.9M-29.8% | $1.8M-48.6% | $869K+189.2% | -$3.7M-231.7% | $4.1M+22.1% | $3.4M-9.3% |
| Depreciation & Amortization | $423K+5.1% | $404K+4.2% | $433K+22.6% | $447K-64.0% | $402K-73.6% | $388K-72.3% | $353K+7.1% | $1.2M-47.2% |
| Stock-Based Compensation | N/A | $280K-4.7% | N/A | N/A | N/A | $294K-40.4% | N/A | N/A |
| Capital Expenditures | $256K-49.3% | $235K-29.2% | $349K+22.9% | $318K+30.3% | $505K+92.5% | $332K-16.1% | $284K-75.6% | $244K-77.9% |
| Free Cash Flow | $1.9M+432.4% | -$1.7M+57.6% | $2.5M-33.7% | $1.5M-54.6% | $364K+129.4% | -$4.0M-266.9% | $3.8M+73.5% | $3.2M+18.7% |
| Investing Cash Flow | $904K-87.5% | -$235K+19.5% | -$349K-235.1% | -$318K-238.3% | $7.2M+8281.9% | -$291K+15.5% | -$104K+92.0% | -$94K+91.5% |
| Financing Cash Flow | -$695K | -$1.2M-230.4% | -$9.0M-35937.8% | -$1.7M-27096.8% | $0-100.0% | $893K+144.4% | -$25K-300.6% | -$6K+12.7% |
| Share Buybacks | $677K | $1.1M | $9.0M | $2.3M+23786.0% | $0-100.0% | $0-100.0% | $0-100.0% | -$10K+701.9% |
Not reported in any period shown, so not listed: Dividends Paid.
JYNT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.7%+4.6pp | 81.6%+4.4pp | 81.4%+3.1pp | 80.1%-10.6pp | 79.1%-11.6pp | 77.3%-13.6pp | 78.3%+0.7pp | 90.7%-0.5pp |
| Operating Margin | -2.4%+6.2pp | 5.9%+11.1pp | 4.9%-0.6pp | 1.2%+2.8pp | -8.6%-2.7pp | -5.2%-3.8pp | 5.5%-2.3pp | -1.6%-1.6pp |
| Net Margin | 4.3%+3.6pp | 8.8%+1.4pp | 6.5%+6.4pp | 6.4%+16.9pp | 0.7%+12.6pp | 7.4%+4.2pp | 0.1%+87.0pp | -10.5%-8.1pp |
| Return on Equity | 4.1%+3.7pp | 8.4%+4.2pp | 6.6%+6.5pp | 3.8%+19.3pp | 0.4%+15.9pp | 4.2%+0.6pp | 0.1%+44.7pp | -15.5%-13.5pp |
| Return on Assets | 1.3%+1.1pp | 2.2%+1.0pp | 1.6%+1.6pp | 1.2%+5.2pp | 0.1%+4.5pp | 1.2%+0.1pp | 0.0%+12.7pp | -4.0%-3.3pp |
| Current Ratio | 1.830.0x | 1.640.0x | 1.59+0.1x | 1.83+0.4x | 1.80+0.5x | 1.66+0.3x | 1.52+0.2x | 1.44+0.4x |
| Debt-to-Equity | 2.26+0.1x | 2.74+0.2x | 3.050.0x | 2.06-0.8x | 2.15-0.4x | 2.51+0.2x | 3.02+0.5x | 2.89+1.1x |
| Asset Turnover | 0.29+0.1x | 0.26+0.1x | 0.25+0.1x | 0.19-0.2x | 0.18-0.2x | 0.16-0.2x | 0.180.0x | 0.38+0.1x |
| FCF Margin | 12.8%+10.0pp | -11.5%+19.3pp | 16.8%-9.3pp | 10.9%+0.3pp | 2.7%+6.8pp | -30.8%-39.0pp | 26.1%+8.7pp | 10.6%+1.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| The Joint Corp. JYNT | FY2025 | $54.9M | $2.9M | 5.3% | $111.0M | 27/100 |
| Biote Corp. BTMD | FY2025 | $192.2M | $27.0M | 14.1% | $37.6M | 53/100 |
| DocGo Inc. DCGO | FY2025 | $322.2M | -$196.4M | -61.0% | $36.6M | 37/100 |
| The Oncology Institute, Inc. TOI | FY2025 | $502.7M | N/A | N/A | $512.9M | 34/100 |
| Enhabit, Inc. EHAB | FY2025 | $1.1B | -$4.6M | -0.4% | $706.9M | 29/100 |
| Community Health Systems, Inc. CYH | FY2025 | $12.5B | $509.0M | 4.1% | $407.5M | 40/100 |
Where The Joint Corp. Ranks
Frequently Asked Questions
What is The Joint Corp.'s annual revenue?
The Joint Corp. (JYNT) reported $54.9M in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is The Joint Corp.'s revenue growing?
The Joint Corp. (JYNT) revenue grew by 5.2% year-over-year, from $52.2M to $54.9M in fiscal year 2025.
Is The Joint Corp. profitable?
Yes, The Joint Corp. (JYNT) reported a net income of $2.9M in fiscal year 2025, with a net profit margin of 5.3%.
What is The Joint Corp.'s EBITDA?
The Joint Corp. (JYNT) had EBITDA of $800K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is The Joint Corp.'s gross margin?
The Joint Corp. (JYNT) had a gross margin of 79.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is The Joint Corp.'s operating margin?
The Joint Corp. (JYNT) had an operating margin of -1.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is The Joint Corp.'s net profit margin?
The Joint Corp. (JYNT) had a net profit margin of 5.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is The Joint Corp.'s return on equity (ROE)?
The Joint Corp. (JYNT) has a return on equity of 19.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is The Joint Corp.'s free cash flow?
The Joint Corp. (JYNT) generated $335K in free cash flow during fiscal year 2025. This represents a -95.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is The Joint Corp.'s operating cash flow?
The Joint Corp. (JYNT) generated $1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are The Joint Corp.'s total assets?
The Joint Corp. (JYNT) had $61.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are The Joint Corp.'s capital expenditures?
The Joint Corp. (JYNT) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is The Joint Corp.'s current ratio?
The Joint Corp. (JYNT) had a current ratio of 1.59 as of fiscal year 2025, which is generally considered healthy.
What is The Joint Corp.'s debt-to-equity ratio?
The Joint Corp. (JYNT) had a debt-to-equity ratio of 3.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is The Joint Corp.'s return on assets (ROA)?
The Joint Corp. (JYNT) had a return on assets of 4.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is The Joint Corp.'s P/E ratio?
The Joint Corp. (JYNT) trades at 29.2x earnings, its market capitalization divided by net income of $3.8M net income, trailing 12 months to June 30, 2026. The market capitalization is $111.0M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is The Joint Corp.'s price-to-sales ratio?
The Joint Corp. (JYNT) trades at 1.9x sales, its market capitalization divided by revenue of $58.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $111.0M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is The Joint Corp.'s Altman Z-Score?
The Joint Corp. (JYNT) has an Altman Z-Score of 2.11, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is The Joint Corp.'s Piotroski F-Score?
The Joint Corp. (JYNT) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are The Joint Corp.'s earnings high quality?
The Joint Corp. (JYNT) has an earnings quality ratio of 0.63x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is The Joint Corp.?
The Joint Corp. (JYNT) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.